Purple Biotech Ltd (KTOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Purple Biotech Ltd (KTOV) has a cash flow conversion efficiency ratio of -0.041x as of June 2020. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.32 Million ≈ $-6.22K USD) by net assets (ILA56.15 Million ≈ $150.52K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KTOV days of operational coverage to measure how many days the company can operate on defensive assets alone.
Purple Biotech Ltd - Cash Flow Conversion Efficiency Trend (2013–2019)
This chart illustrates how Purple Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Purple Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
S2Medical AB
ST:S2M
|
0.068x |
|
MOVEBYBIKE EUROPE AB
F:6ZR
|
-7.892x |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA
|
-0.009x |
|
PURANIUM ENERGY LTD.
F:2DK
|
0.113x |
|
Time Out Group plc
LSE:TMO
|
-0.052x |
|
SECITS Holding AB (publ)
ST:SECI
|
0.666x |
|
GetBusy PLC
LSE:GETB
|
-0.033x |
|
Churchill China plc
LSE:CHH
|
0.123x |
Annual Cash Flow Conversion Efficiency for Purple Biotech Ltd (2013–2019)
The table below shows the annual cash flow conversion efficiency of Purple Biotech Ltd from 2013 to 2019. For the full company profile with market capitalisation and key ratios, see how much is Purple Biotech Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2019-12-31 | ILA10.86 Million ≈ $29.11K |
ILA-5.58 Million ≈ $-14.96K |
-0.514x | +33.31% |
| 2018-12-31 | ILA11.00 Million ≈ $29.50K |
ILA-8.48 Million ≈ $-22.73K |
-0.771x | +23.24% |
| 2017-12-31 | ILA8.59 Million ≈ $23.04K |
ILA-8.63 Million ≈ $-23.13K |
-1.004x | -114.60% |
| 2016-12-31 | ILA13.38 Million ≈ $35.88K |
ILA-6.26 Million ≈ $-16.79K |
-0.468x | -33.35% |
| 2015-12-31 | ILA9.43 Million ≈ $25.28K |
ILA-3.31 Million ≈ $-8.87K |
-0.351x | +93.40% |
| 2014-12-31 | ILA851.00K ≈ $2.28K |
ILA-4.53 Million ≈ $-12.13K |
-5.318x | -1082.67% |
| 2013-12-31 | ILA-946.00K ≈ $-2.54K |
ILA-512.00K ≈ $-1.37K |
0.541x | -- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more